Featuring perspectives from Dr Matthew D Galsky, Dr Shilpa Gupta, Dr Terence Friedlander and Prof Andrea Necchi, moderated by Dr Friedlander. Published March 2026.
Credit & MOC Details
Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.
Credit types
AMA PRA Category 1 Credit™Up to 2.25 credits
MOC types
ABS — Accredited CMEUp to 2.25 pointsABIM — Medical KnowledgeUp to 2.25 pointsABS — Self-AssessmentUp to 2.25 points
FDA REMS
No
Qualifies for MIPS
No
Target Specialties
Pricing
100% of listed courses are free
240 of 240 courses listed here are free.
Collected from the provider’s public pages
Specialties served/covered
- No reviews yet. Be the first to share yours.
Pricing
Free
Reported to ACCME by the provider
- On-demand / recorded video
- Credit · Up to 2.25 credits
- MOC · Up to 2.25 points
-
ReleasedMar 25, 2026
-
Last day to claim creditMar 27, 2027 6 months left
-
Research to Practice Second Opinion: Integrating Novel Approaches into the Management of Non-Muscle-Invasive and Muscle-Invasive Bladder Cancer | 2026 (Symposium Audio Proceedings)
-
Research to Practice Second Opinion: Investigators Provide Perspectives on the Current and Future Management of Prostate Cancer | 2026 (Symposium Proceedings)
-
Research to Practice Rapid Case Review: Investigators Provide Perspectives on Actual Cases of Metastatic Bladder Cancer Issue 2 | 2026 (Video Program)
-
National Comprehensive Cancer Network Archived NCCN Tumor Boards: New and Emerging Treatment Options for Non-Muscle-Invasive and Muscle-Invasive Bladder Cancer
-
PRIME Education, Inc. (PRIME®) Shaping the Future of Muscle-Invasive Bladder Cancer Treatment With the Integration of Immunotherapy and Multidisciplinary Care
-
Physicians’ Education Resource Medical Crossfire(R): Breakthroughs in Non-Muscle-Invasive Bladder Cancer: Advancing Patient Care Through Innovation in Treatment
